We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cell Subtype Found to Promote Graft Acceptance

By HospiMedica staff writers
Posted on 28 May 2001
A study has shown that a subtype of dendritic cell plays a key role in preventing organ rejection and may be associated with the long-term survival of a transplanted organ without the need for immunosuppressant drugs. More...
The study was conducted by researchers at the University of Pittsburgh School of Medicine (PA, USA) and presented at Transplant 2001 in Chicago. The findings are significant because dendritic cells have been thought to be involved only in promoting the rejection process.

The researchers found that a pre-transplant infusion of lymphoid dendritic cell subtypes derived from tissue such as the spleen allowed for prolonged survival in a mouse heart transplant model, even without the use of drugs to control rejection. In contrast, myeloid dendritic cells accelerated the rejection response. The research team wants to find out if the lymphoid dendritic cells are present in liver and kidney transplant recipients who have been successfully weaned off immunosuppression, in order to better understand the specific immunologic process that occurs in these patients.

Specifically, the team is examining the role of dendritic cells in tolerance as well as key regulatory proteins within the immune system, where small changes in the code may reveal a patient's potential for rejection. "This will provide a road map for clinicians to help identify those for whom immunosuppression can be safely withdrawn, "said Dr. Thomson, professor of surgery and molecular genetics at the University of Pittsburgh School of Medicine.



Related Links:
Univ. of Pittsburgh

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.